These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G. Vaccine; 2018 Dec 18; 36(52):8069-8078. PubMed ID: 30389195 [Abstract] [Full Text] [Related]
11. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. Jacobino SR, Nederend M, Reijneveld JF, Augustijn D, Jansen JHM, Meeldijk J, Reiding KR, Wuhrer M, Coenjaerts FEJ, Hack CE, Bont LJ, Leusen JHW. MAbs; 2018 Apr 18; 10(3):453-462. PubMed ID: 29553863 [Abstract] [Full Text] [Related]
12. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE. Virology; 2014 Apr 18; 454-455():139-44. PubMed ID: 24725940 [Abstract] [Full Text] [Related]
13. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group. BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274 [Abstract] [Full Text] [Related]
14. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Weisman LE. Curr Opin Mol Ther; 2009 Apr 03; 11(2):208-18. PubMed ID: 19330726 [Abstract] [Full Text] [Related]